Compare iShares Core S&P 500 ETF (IVV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs 10X Genomics Inc — how do they compare? iShares Core S&P 500 ETF trades at $780.81 (market cap $897.20B), while 10X Genomics Inc trades at $78.99 (market cap $10.07B). The key difference: iShares Core S&P 500 ETF is far larger — about 89.1× 10X Genomics Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core S&P 500 ETF for 46 Days and 10X Genomics Inc for 92 Days on average.
| IVV | TXG | |
|---|---|---|
Market Cap | $897.20B | $10.07B |
Volume | 4,580,672 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $782.58 | $97.74 |
52-Week Low | $634.93 | $11.48 |
Typical Hold Time | 46 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $780.6, down 0.25% on the day. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions near-term. The ETF benefits from diversified exposure to large-cap US equities, with recent news highlighting strong corporate earnings growth expectations of 35% for 2026. Market sentiment remains mixed amid concerns about valuation and profit growth normalization.
Outlook remains cautiously optimistic given the S&P 500's historical bullish seasonal patterns and strong institutional support. Key risks include elevated Treasury yields, concentration in top holdings, and potential earnings growth deceleration to 15% in 2027. The ETF's low-cost structure and broad market exposure provide defensive characteristics during market volatility.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
